LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: An immunohistochemical survey of 602 gastrointestinal tract neoplasms

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 10, 2014, Pages 728-734

  Kermanshahi, Taher R ^a   Jayachandran, Priya ^b   Chang, Daniel T ^b   Pai, Reet ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

BRAF; Colorectal carcinoma; KRAS; LEF 1; MSI; Prognosis

Indexed keywords

CDX2 PROTEIN, HUMAN; CYTOKERATIN 20; HOMEODOMAIN PROTEIN; KRAS PROTEIN, HUMAN; KRT20 PROTEIN, HUMAN; LEF1 PROTEIN, HUMAN; LYMPHOID ENHANCER FACTOR 1; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; CELL NUCLEUS; COLORECTAL NEOPLASMS; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; PROTEIN TRANSPORT; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84914122707     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000109     Document Type: Article

References (29)

1. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113-130.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623-627.
3. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-96.
4. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/betacatenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142:219-232.
5. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-850.
6. Albuquerque C, Baltazar C, Filipe B, et al. Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer. 2010;49:746-759.
7. Brabletz T, Jung A, Hermann K, et al. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract. 1998;194:701-704.
8. Anderson CB, Neufeld KL, White RL. Subcellular distribution of Wnt pathway proteins in normal and neoplastic colon. Proc Natl Acad Sci U S A. 2002;99:8683-8688.
9. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: a mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci U S A. 2000;97:3352-3357.
10. Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5:a007898.
11. Waterman ML, Fischer WH, Jones KA. A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer. Genes Dev. 1991;5:656-669.
12. Travis A, Amsterdam A, Belanger C, et al. LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]. Genes Dev. 1991;5:880-894.
13. Tandon B, Peterson L, Gao J, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol. 2011;24:1433-1443.
14. Walther N, Ulrich A, Vockerodt M, et al. Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt's lymphoma. Am J Pathol. 2013;182:1092-1098.
15. Kuhnl A, Gokbuget N, Kaiser M, et al. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood. 2011;118:6362-6367.
16. Kriegl L, Horst D, Reiche JA, et al. LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med. 2010;8:123-131.
17. Lin AY, Chua MS, Choi YL, et al. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One. 2011;6:e16636.
18. Wang WJ, Yao Y, Jiang LL, et al. Increased LEF1 expression and decreased notch2 expression are strong predictors of poor outcomes in colorectal cancer patients. Dis Markers. 2013;35:395-405.
19. Kim JH, Rhee YY, Bae JM, et al. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatelliteunstable colorectal cancer. Am J Surg Pathol. 2013;37:1532-1541.
20. Lugli A, Tzankov A, Zlobec I, et al. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol. 2008;21:1403-1412.
21. McGregor DK, Wu TT, Rashid A, et al. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol. 2004;28:712-718.
22. Zlobec I, Bihl M, Foerster A, et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol. 2011;225:336-343.
23. Gurzu S, Jung I. Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. Pathol Res Pract. 2012;208:163-166.
24. Gurzu S, Szentirmay Z, Toth E, et al. Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition. PLoS One. 2013;8:e57699.
25. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002;161:1557-1565.
26. Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol. 2001;159:2107-2116.
27. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol. 1990;3:332-335.
28. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33:134-141.
29. Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012;36:744-752.